ArticleThe Journal of experimental medicine1995
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.
Article in The Journal of experimental medicine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 667 citations in OpenAlex.
- PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.International journal of clinical oncology · 2010Trial
- Effects of lornoxicam on the physiology of severe sepsis.Critical care (London, England) · 2004Trial
- Immune responses and prediction of major infection in patients undergoing transhiatal or transthoracic esophagectomy for cancer.Annals of surgery · 2003Trial
- Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia.The Journal of clinical investigation · 1996Trial
- Bioengineered Pancreatic Cancer Immunosuppressive Microenvironment Models for Screening Immunotherapies.Advanced healthcare materials · 2026Article
- Treatment of cancer-associated fibroblast-like cells with celecoxib enhances the anti-cancer T helper 1/Treg responses in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects.Pharmaceutics · 2024Review
- The impact of trauma relevant concentrations of prostaglandin EFrontiers in immunology · 2024Article
- Macrophages in Lung Repair and Fibrosis.Results and problems in cell differentiation · 2024Review
- Harnessing prostaglandin ETrends in immunology · 2023Review
- Mast cell-mediated immune regulation in health and disease.Frontiers in medicine · 2023Review
- Involvement of the Innate Immune System in the Pathogenesis of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2022Review
- Utilizing mast cells in a positive manner to overcome inflammatory and allergic diseases.Frontiers in immunology · 2022Review
- Utilising Network Pharmacology to Explore Underlying Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Biological Characteristics of Umbilical Cord Mesenchymal Stem Cells and Its Therapeutic Potential for Hematological Disorders.Frontiers in cell and developmental biology · 2021Review
- Transcriptomic Analysis of Ovine Hepatic Lymph Node FollowingFrontiers in immunology · 2021Article
- Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.Frontiers in immunology · 2021Review
- Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19.British journal of pharmacology · 2020Review
- Proinflammatory α-Adrenergic Neuronal Regulation of Splenic IFN-γ, IL-6, and TGF-β of Mice from Day 15 onwards in Arthritis.Neuroimmunomodulation · 2020Article
- Granulocytic Myeloid-Derived Suppressor Cell Exosomal Prostaglandin E2 Ameliorates Collagen-Induced Arthritis by Enhancing IL-10Frontiers in immunology · 2020Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During human immunodeficiency virus infection and allergic diseases, characterized by a dominant T helper (Th) 2 response, overproduction of prostaglandin E2 (PGE2) is observed. In this paper we studied the effect of PGE2 on interleukin (IL)-12 synthesis, because this cytokine has been described to be essential in induction of Th1 responses. IL-12 synthesis was induced in monocytes that were stimulated with Neisseria meningitidis-derived lipopolysaccharide in whole blood cultures. PGE2 almost completely inhibited lipopolysaccharide induced IL-12 production, whereas IL-6 production was only partially inhibited by PGE2. In contrast, the production of IL-10 was approximately twofold enhanced at these conditions. The effects of PGE2 were due to its cAMP-inducing capacity, since they could be mimicked by other cAMP inducers. Recombinant human IL-10 also inhibited IL-12 and IL-6 production. However, the inhibitory effect of PGE2 on IL-12 production was independent of IL-10 since neutralizing anti-IL-10 antibodies were unable to reverse this inhibition. These results suggest that the capacity of an antigen to induce PGE2 synthesis may play a crucial role in the development of either a Th1 or Th2 response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.